Glenmark confirms patent challenge for generic Finacea

Glenmark Generics confirms that it has filed an ANDA for Azelaic Acid, Gel 15% Topical, with the USFDA with a Paragraph IV Certification for the Orange-Book listed patent

conceptual-shot-depicting-shutterstock-10685842

Glenmark Pharmaceuticals, a manufacturer of generic formulation products and active pharmaceutical ingredients (API), has confirmed that it has filed an Abbreviated New Drug Application (ANDA) for Azelaic Acid, Gel 15 percent Topical, with the US Food and Drug Administration (FDA). Glenmark's ANDA product is a generic version of Finacea, which is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

Intendis GmbH, Intraserv GmbH and Co, and Bayer Healthcare Pharmaceuticals had filed a suit against Glenmark Generics on March 14, 2013, in the United States District Court for the District of Delaware, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of US patent number 6,534,070. This lawsuit was filed under the provisions of the Hatch-Waxman Act, which triggers a stay of final FDA approval of Glenmark's ANDA product for up to 30 months or until final resolution of the matter before the Court, whichever occurs sooner.

Based on available information, Glenmark believes it may be a "first applicant" to file an ANDA for the generic version of Finacea and may be entitled to 180 days of generic market exclusivity.

According to the IMS health data for the twelve months ending September 30, 2012, Finacea had total US sales of approximately $95 million.

2 Comment Comment 1 - 2 of 2
comment

dwbhslkftp 10 April 2013 at 12:05 PM

v6hr9s a href="http://gftbplaansnz.com/" gftbplaansnz /a

Reply

comment

Loo 10 April 2013 at 04:15 AM

I guess there is a fine line between (1) impverod user experience which is made possible by software freedom and (2) FOSS ideology for its own sake. If I understand you correctly it is this line which you, reasonably, refuse to cross. While you and I agree that ultimately it's the user experience which ultimately matters, people of one camp leave product quality out of it while others leave the user's freedom out of it. An inclusive vision is what's needed.I am not a FOSS fanatic but I do believe that the user's freedom is an important component of user experience, which is what people like you and I care about. But yes, it's only a component and not the end goal in itself. We should take care not to fall in trap of optimizing locally and forgetting the big picture.

Reply

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X